Form 4: Abbott Labs Director Reports Stock Unit Transactions
Statement of Changes in Beneficial Ownership
Abbott Laboratories Director Patricia Paola Gonzalez reported transactions involving stock equivalent units, reflecting director fees and dividend reinvestment.
Summary
- Patricia Paola Gonzalez, a Director at Abbott Laboratories, reported transactions related to her beneficial ownership of company securities.
- The transactions involve stock equivalent units, which represent director fees credited to an account under a grantor trust.
- These units earn returns equivalent to investing in Abbott shares and are generally paid in cash at age 65 or upon retirement from the board.
- The reported activity includes the acquisition of 321 stock equivalent units on March 31, 2026, valued at $102.67 per unit.
- The total balance of securities beneficially owned following these transactions is 5,558 stock equivalent units.
- The balance also includes units acquired through a dividend reinvestment feature.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing, as it represents routine insider reporting of director compensation and reinvestment, rather than significant strategic or financial events.
Positives
- Director Gonzalez's holdings reflect ongoing participation and investment in the company through director fees.
- The dividend reinvestment feature indicates a mechanism for increasing beneficial ownership over time.
Future Outlook
The filing does not contain forward-looking statements or guidance regarding future financial performance.
Industry Context
StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions, providing transparency into the holdings and activities of company directors and officers. This specific filing details how director compensation is structured and reinvested within Abbott Laboratories.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Director Compensation Structure | Director fees are credited to a stock equivalent unit account under a grantor trust, earning returns equivalent to Abbott shares. | Not specified, but ongoing | Enhances alignment between director compensation and shareholder value through stock-based returns. |
| Dividend Reinvestment | Stock equivalent units acquire additional units through a dividend reinvestment feature. | Not specified, but ongoing | Allows for compounding of beneficial ownership for directors over time. |
Related Party Transactions
- Director fees paid to Patricia Paola Gonzalez in the form of stock equivalent units.
Stakeholder Impact
- Shareholders: Increased transparency into director compensation and reinvestment practices.
Key Dates
| Date | Description |
|---|---|
| 03/31/2026 | Date of earliest transaction and transaction date for acquisition of stock equivalent units. |
| 04/02/2026 | Date of signature for the filing. |
Keywords
Form 4, SEC Filing, Abbott Laboratories, ABT, Director, Stock Equivalent Units, Beneficial Ownership, Insider Trading, Grantor Trust, Dividend Reinvestment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.